Do we know the total headcount of patients that had taken Bril altogether? That's just safety profile of drug as to why they'll be testing Bril Phase II patients in CV19 patients?
Bril could be worth as much as a 10b tag price since its the flagship. Cv19 trials will help us get to $3b+ valuation. Maybe $5b cash upfront plus up to $5b in CVR? Ipix can throw in K for free!